全文获取类型
收费全文 | 218346篇 |
免费 | 4020篇 |
国内免费 | 172篇 |
专业分类
耳鼻咽喉 | 1601篇 |
儿科学 | 7614篇 |
妇产科学 | 3855篇 |
基础医学 | 21666篇 |
口腔科学 | 2690篇 |
临床医学 | 16922篇 |
内科学 | 39806篇 |
皮肤病学 | 1144篇 |
神经病学 | 19838篇 |
特种医学 | 10347篇 |
外国民族医学 | 1篇 |
外科学 | 36057篇 |
综合类 | 3013篇 |
一般理论 | 26篇 |
预防医学 | 21472篇 |
眼科学 | 3998篇 |
药学 | 12328篇 |
中国医学 | 678篇 |
肿瘤学 | 19482篇 |
出版年
2023年 | 187篇 |
2022年 | 358篇 |
2021年 | 856篇 |
2020年 | 518篇 |
2019年 | 764篇 |
2018年 | 22706篇 |
2017年 | 17907篇 |
2016年 | 20138篇 |
2015年 | 1756篇 |
2014年 | 2046篇 |
2013年 | 2694篇 |
2012年 | 9671篇 |
2011年 | 23719篇 |
2010年 | 20298篇 |
2009年 | 12929篇 |
2008年 | 21950篇 |
2007年 | 24238篇 |
2006年 | 3225篇 |
2005年 | 4986篇 |
2004年 | 6080篇 |
2003年 | 6835篇 |
2002年 | 4848篇 |
2001年 | 792篇 |
2000年 | 848篇 |
1999年 | 701篇 |
1998年 | 778篇 |
1997年 | 666篇 |
1996年 | 496篇 |
1995年 | 491篇 |
1994年 | 415篇 |
1993年 | 362篇 |
1992年 | 373篇 |
1991年 | 356篇 |
1990年 | 387篇 |
1989年 | 323篇 |
1988年 | 283篇 |
1987年 | 271篇 |
1986年 | 233篇 |
1985年 | 266篇 |
1984年 | 324篇 |
1983年 | 327篇 |
1982年 | 419篇 |
1981年 | 360篇 |
1980年 | 368篇 |
1979年 | 193篇 |
1978年 | 230篇 |
1977年 | 225篇 |
1976年 | 214篇 |
1975年 | 175篇 |
1974年 | 173篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
ABSTRACTIn clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the test treatment under study. For example, in cancer clinical trials, overall survival, response rate, and/or time to disease progression are usually considered as primary clinical endpoints for evaluation of safety and effectiveness of the test treatment under investigation. Once the study endpoints have been selected, sample size required for achieving a desired power is then determined. It, however, should be noted that different study endpoints may result in different sample sizes. In practice, it is usually not clear which study endpoint can best inform the disease status and measure the treatment effect. Moreover, different study endpoints may not translate one another although they may be highly correlated one another. In this article, we intend to develop an innovative endpoint namely therapeutic index based on a utility function to combine and utilize information collected from all study endpoints. Statistical properties and performances of the proposed therapeutic index are evaluated theoretically. A numerical example concerning a cancer clinical trial is given to illustrate the use of the proposed therapeutic index. 相似文献
3.
Seyed Mehdi BagheriMofidi Majid Pouladian Seyed Behnamedin Jameie Ali Abbaspour Tehrani-Fard 《Australasian physical & engineering sciences in medicine / supported by the Australasian College of Physical Scientists in Medicine and the Australasian Association of Physical Sciences in Medicine》2016,39(3):717-726
Magnetic field generated by neuronal activity could alter magnetic resonance imaging (MRI) signals but detection of such signal is under debate. Previous researches proposed that magnitude signal change is below current detectable level, but phase signal change (PSC) may be measurable with current MRI systems. Optimal imaging parameters like echo time, voxel size and external field direction, could increase the probability of detection of this small signal change. We simulate a voxel of cortical column to determine effect of such parameters on PSC signal. We extended a laminar network model for somatosensory cortex to find neuronal current in each segment of pyramidal neurons (PN). 60,000 PNs of simulated network were positioned randomly in a voxel. Biot–savart law applied to calculate neuronal magnetic field and additional phase. The procedure repeated for eleven neuronal arrangements in the voxel. PSC signal variation with the echo time and voxel size was assessed. The simulated results show that PSC signal increases with echo time, especially 100/80 ms after stimulus for gradient echo/spin echo sequence. It can be up to 0.1 mrad for echo time = 175 ms and voxel size = 1.48 × 1.48 × 2.18 mm3. With echo time less than 25 ms after stimulus, it was just acquired effects of physiological noise on PSC signal. The absolute value of the signal increased with decrease of voxel size, but its components had complex variation. External field orthogonal to local surface of cortex maximizes the signal. Expected PSC signal for tactile detection in the somatosensory cortex increase with echo time and have no oscillation. 相似文献
4.
5.
6.
The human visual system is amenable to a number of adaptive processes; one such process, or collection of processes, is the adaptation to blur. Blur adaptation can be observed as an improvement in vision under degraded conditions, and these changes occur relatively rapidly following exposure to blur. The potential important future directions of this research area and the clinical implications of blur adaptation are discussed. 相似文献
7.
8.
9.
10.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献